
An improved long-term sales target today revitalised GSK shares after their dismal 2024.
The confidence in GSK’s drugs pipeline came alongside results pointing to top line growth between 3% and 5% in 2025.

An improved long-term sales target today revitalised GSK shares after their dismal 2024.
The confidence in GSK’s drugs pipeline came alongside results pointing to top line growth between 3% and 5% in 2025.